Marco legal vigente y aspectos prácticos de la oxigenoterapia durante los viajes en avión / Current Legal Framework and Practical Aspects of Oxygen Therapy During Air Travel

En el entorno neumológico no es habitual conocer las normativas europeas y de EE. UU. que regulan la administración de oxígeno durante los viajes en avión y la política a tal respecto que cada compañía aérea tiene. Este desconocimiento se debe en gran parte a la escasez de artículos que abordan este tema en las revistas especializadas y a la llamativamente limitada información que nos proporcionan las aerolíneas en sus páginas web. En este artículo hemos abordado estas normativas, la política que siguen algunas aerolíneas y determinados aspectos prácticos que deberíamos tener en cuenta, para que podamos responder de forma satisfactoria a las preguntas que, en un momento puntual, nos pueda plantear un paciente que necesite utilizar oxígeno durante los viajes en avión

It is unusual for pulmonologists to be familiar with the European and US regulations governing the administration of oxygen during air travel and each airline’s policy in this respect. This lack of knowledge is in large part due to the scarcity of articles addressing this matter in specialized journals and the noticeably limited information provided by airlines on their websites. In this article we examine the regulations, the policies of some airlines and practical aspects that must be taken into account, so that the questions of a patient who may need to use oxygen during a flight may be answered satisfactorily

Current legal framework and practical aspects of oxygen therapy during air travel.

It is unusual for pulmonologists to be familiar with the European and US regulations governing the administration of oxygen during air travel and each airline's policy in this respect. This lack of knowledge is in large part due to the scarcity of articles addressing this matter in specialized journals and the noticeably limited information provided by airlines on their websites. In this article we examine the regulations, the policies of some airlines and practical aspects that must be taken into account, so that the questions of a patient who may need to use oxygen during a flight may be answered satisfactorily.

Evaluación de la utilización de una consulta de diagnóstico rápido de cáncer de pulmón. Tiempos de demora diagnóstica y terapéutica / Evaluation of the Use of a Rapid Diagnostic Consultation of Lung Cancer. Delay Time of Diagnosis and Therapy

Objetivo: Analizar los resultados conseguidos desde su creación hace 5 años en una consulta de diagnóstico rápido de cáncer de pulmón (CDR-CP) relacionados con el buen uso de la derivación, tiempos de demora diagnóstica y terapéutica, y días de estancia hospitalaria. Comparar las demoras diagnóstico-terapéuticas y estancias hospitalarias con las obtenidas en los pacientes evaluados mediante la sistemática habitual (NCDR-CP). Pacientes y método: Se ha incluido a todos los pacientes valorados en nuestra CDR-CP en los últimos 5 años. En los CP se han registrado las fechas de derivación al médico especialista, primera consulta, realización de pruebas diagnósticas, estadificación, inicio del tratamiento y días de hospitalización. Se han comparado estos mismos datos con los pacientes NCDR-CP diagnosticados en el periodo de octubre 2008 a octubre de 2010. Resultados: Se evaluaron 179 pacientes remitidos a CDR-CP que representan el 26,7% de las consultas ofertadas, siendo 166 (92,7%) las remisiones correctas, de las que el 44,5% correspondieron a un CP; en el 75,6% de ellos se realizó todo el estudio de forma ambulatoria y más del 85% de los casos cumplían con las recomendaciones existentes relacionadas con las demoras diagnóstico-terapéuticas. Al comparar estos datos con el grupo NCDR-CP (n=151), se encontraron diferencias relacionadas con los datos de hospitalización: menor porcentaje de ingresados (p<0,0001) y menos días de estancia (p<0,0001) en el grupo CDR-CP. No existieron diferencias entre ambos grupos en las demoras diagnósticas y terapéuticas. Conclusión: En nuestro medio la consulta de diagnóstico rápido de cáncer de pulmón permite realizar, en un gran porcentaje de casos, todos los estudios de forma ambulatoria y en plazos de tiempo acordes con las recomendaciones existentes. Pese a ello, hemos detectado una acusada infrautilización de las mismas(AU)

Objective: To analyze the results obtained in a lung cancer screening program since its inception five years ago regarding correct referrals, diagnostic and therapeutic delay times and days of hospitalization. To compare the diagnostic-therapeutic delays and hospital stays with those obtained in patients evaluated with the standard system. Patients and methods: Included for study were all those patients evaluated in our Lung Cancer Screening Program (LCSP) in the last five years. For the cases with LC, we recorded the dates the patients were referred to a specialist, the first consultation, diagnostic tests, stage, start of treatment and days of hospitalization. We compared these same data with lung cancer patients who did not partake in the LCSP and were diagnosed between October 2008 and October 2010. Results: We evaluated 179 patients remitted to the LCSP, which represented 26.7% of the consultations; 166 (92.7%) of the referrals were correct, out of which 44.5% were LC. In 75.6% of these, the entire study was completed in the outpatient setting, and more than 85% of the cases met the current recommendations related with diagnostic-therapeutic delays. When these results were compared with the non-LCSP group (n=151), differences were found in the data for hospitalizations: there was a lower percentage of hospitalizations (P<.0001) and shorter hospital stays (P<.0001) in the LCSP group. There were no differences between the two groups for diagnostic or therapeutic delays. Conclusion: In our setting, lung cancer screening programs allow for cancer studies to be carried out in the outpatient consultations in a large percentage of cases, and within the time periods recommended by current guidelines. In spite of this fact, we have detected that these programs are underused(AU)

Evaluation of the use of a rapid diagnostic consultation of lung cancer. Delay time of diagnosis and therapy.

OBJECTIVE: To analyze the results obtained in a lung cancer screening program since its inception five years ago regarding correct referrals, diagnostic and therapeutic delay times and days of hospitalization. To compare the diagnostic-therapeutic delays and hospital stays with those obtained in patients evaluated with the standard system. PATIENTS AND METHODS: Included for study were all those patients evaluated in our Lung Cancer Screening Program (LCSP) in the last five years. For the cases with LC, we recorded the dates the patients were referred to a specialist, the first consultation, diagnostic tests, stage, start of treatment and days of hospitalization. We compared these same data with lung cancer patients who did not partake in the LCSP and were diagnosed between October 2008 and October 2010. RESULTS: We evaluated 179 patients remitted to the LCSP, which represented 26.7% of the consultations; 166 (92.7%) of the referrals were correct, out of which 44.5% were LC. In 75.6% of these, the entire study was completed in the outpatient setting, and more than 85% of the cases met the current recommendations related with diagnostic-therapeutic delays. When these results were compared with the non-LCSP group (n=151), differences were found in the data for hospitalizations: there was a lower percentage of hospitalizations (P<.0001) and shorter hospital stays (P<.0001) in the LCSP group. There were no differences between the two groups for diagnostic or therapeutic delays. CONCLUSION: In our setting, lung cancer screening programs allow for cancer studies to be carried out in the outpatient consultations in a large percentage of cases, and within the time periods recommended by current guidelines. In spite of this fact, we have detected that these programs are underused.